What goes up must come down and Gilead Sciences knows this better than most. Shares of the biotechnology company slipped on Friday despite a 54% jump in profit after rising prior to the release of the company’s second-quarter earnings report. The reason? Lower-than-expected sales of HIV drug Atripla.
